The animal testing of the elixir for future warfare has been a success. Now the most difficult thing remains: making it work in humans
In 1667, the French doctor Jean-Baptiste Denis performed one of the first transfusions of history using lamb’s blood on a human patient, convinced that it could calm his behavior and save his life. The experiment generated such controversy that ended up being banned in several countries for decades, leaving a lesson that has accompanied medicine since then: when it comes to replacing blood, each advance opens a door… and also a risk that is difficult to foresee. An experiment that redefines war medicine. A lot has happened since that test by Denis, but now it is making strong noises again with the development of a powdered blood substituteone that marks one of the most ambitious advances in military preparation for future conflicts, where conditions no longer guarantee rapid evacuations or immediate access to hospitals. In this context, the idea of transforming blood into a portable and stable resource ceases to be science fiction and becomes a solution, or perhaps an operational necessity. They counted on Insider that, for the Pentagon, what is at stake is not only improving logistics, but changing the way soldiers’ lives are saved in environments where every minute counts and medical infrastructure may not exist. The “elixir” that seeks to change war. The program powered by DARPA has managed to turn a complex concept into a potentially revolutionary solution: a powdered blood substitute that can be stored, transported and activated in a matter of seconds. This system is presented as an alternative to the current model, where fresh blood is limited, perishable and difficult to move in combat zones. The key, they say, is in its operational simplicity: mix the contents with sterile water and have a vital resource at the exact moment it is needed. Success in the laboratory. The initial results have been promising enough to generate expectations within the military and scientific field. After demonstrating its viability in controlled environments and later in animal models, the project has overcome one of the most complex phases of biomedical development. In other words, the advance suggests that the concept works in biological termsopening the door to real applications in scenarios where conventional transfusions are not possible. The great challenge. There is no doubt, despite of the advancesthe final jump remains the most difficult of all. The next step is to overcome the regulatory processes and demonstrate that the system is safe and effective in humansa long path that involves clinical trials, medical validation and approval from regulatory bodies. In fact, this is where many promising developments stall, not because of a lack of technology, but because of the complexity of ensuring that they work in real conditions without unexpected risks. A necessity. They counted in their report in Insider that interest in this type of solutions does not arise in a vacuum, but as a response to a profound change in the nature of conflicts. Conflicts have shown that air superiority no longer guarantees rapid evacuations, and the wounded can be trapped for hours without access to advanced medical care. In these contexts, the immediate availability of blood becomes a critical factor that can make the difference between life and death. Limitations of the current system. In the absence of alternatives, the armed forces have resorted to methods such as emergency transfusions among soldiers, known as “living blood banks.” Although effective in specific situations, these solutions depend on the availability of donors and cannot scale in scenarios with multiple casualties. Again, this highlights the need for a more robust solution, capable of responding to high-intensity situations without relying on improvised resources. Beyond science. The future of this technology announced by DARPA depends not only on its medical effectiveness, but also on its economic viability. The production, distribution and adoption of synthetic blood require significant investments in a sector where margins are traditionally low. Without a sustainable model that incentivizes companies and hospitals, even the most promising advances can remain in the experimental phase, never reaching the battlefield. Be that as it may, the objective set is more than ambitious: to turn development into an operational tool before end of the decade. To achieve this, almost nothing: coordinate science, regulation and industry in an accelerated process that avoids the usual blockages in such complex projects. But if successful, this sort of modern “elixir” could redefine war medicine, bringing the ability to save lives directly to where it is needed most. Image | DARPA In Xataka | Four years later, the Ukrainian war is the first war in history where humans are spectators In Xataka | In 1914, submachine guns forever changed the way war was waged. In 2026, it’s algorithms’ turn
